Temozolomide 140mg capsules المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

temozolomide 140mg capsules

accord healthcare ltd - temozolomide - capsule - 140mg

Itami 140 mg medicated plaster أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

itami 140 mg medicated plaster

fidia farmaceutici s.p.a. - diclofenac sodium - medicated plaster - 140 milligram(s) - antiinflammatory preparations, non-steroids for topical use; diclofenac

Gabbrovet 140 mg/ml solution for use in drinking water, milk or milk replacer for pre-ruminant cattle and pigs أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

gabbrovet 140 mg/ml solution for use in drinking water, milk or milk replacer for pre-ruminant cattle and pigs

ceva santé animale - paromomycin - solution for use in drinking water/milk - 140 milligram(s)/millilitre - paromomycin - cattle, pigs - antibiotics

Flector Tissugel 140 mg medicated plaster أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

flector tissugel 140 mg medicated plaster

ibsa farmaceutici italia s.r.l - diclofenac epolamine - medicated plaster - 140 milligram(s) - antiinflammatory preparations, non-steroids for topical use; diclofenac

Galfer 140 mg/5ml Oral Suspension أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

galfer 140 mg/5ml oral suspension

clonmel healthcare ltd - ferrous fumarate ph.eur. - oral suspension - 140 mg/5ml - iron bivalent, oral preparations; ferrous fumarate

ESTALIS CONTINUOUS 50/140 estradiol 50mcg/day norethisterone acetate 140mcg/day patch sachet أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

estalis continuous 50/140 estradiol 50mcg/day norethisterone acetate 140mcg/day patch sachet

sandoz pty ltd - norethisterone acetate, quantity: 2.7 mg (equivalent: estradiol, qty 50 microgram; equivalent: norethisterone acetate, qty 140 microgram); estradiol, quantity: 0.62 mg (equivalent: estradiol, qty 50 microgram) - drug delivery system, transdermal - excipient ingredients: oleic acid; dipropylene glycol; povidone; polytrimethylhydrosilylsiloxane; xylene; ammonia; toluene; 1,1,1-trimethyl-n-(trimethylsilyl)silanamine; dimeticonol; polyethylene terephthalate; polyvinylidene flouride; ethyl acetate; ethanol; acrylates/va copolymer; ethylene/vinyl acetate copolymer - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. for prevention of postmenopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estalis continous should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Repatha نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

repatha

amgen new zealand limited - evolocumab 140 mg/ml;   - solution for injection - 140 mg - active: evolocumab 140 mg/ml   excipient: glacial acetic acid polysorbate 80 proline sodium hydroxide water for injection - repatha is indicated as an adjunct to diet and exercise in: hypercholesterolaemia repatha is indicated in adults with primary hypercholesterolaemia (including heterozygous familial hypercholesterolaemia and non-familial hypercholesterolaemia) to reduce low-density lipoprotein cholesterol (ldl-c): - in combination with a statin or statin with other lipid lowering therapies, or - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant. homozygous familial hypercholesterolaemia repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.

Repatha نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

repatha

amgen new zealand limited - evolocumab 140 mg/ml;   - solution for injection - 140 mg - active: evolocumab 140 mg/ml   excipient: glacial acetic acid polysorbate 80 proline sodium hydroxide water for injection - repatha is indicated as an adjunct to diet and exercise in: hypercholesterolaemia repatha is indicated in adults with primary hypercholesterolaemia (including heterozygous familial hypercholesterolaemia and non-familial hypercholesterolaemia) to reduce low-density lipoprotein cholesterol (ldl-c): - in combination with a statin or statin with other lipid lowering therapies, or - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant. homozygous familial hypercholesterolaemia repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.

Estracyt 140 mg hard caps. بلجيكا - الإنجليزية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

estracyt 140 mg hard caps.

pfizer sa-nv - estramustine sodium phosphate monohydrate 156,7 mg - eq. estramustine phosphate 140 mg - capsule, hard - 140 mg - estramustine disodium phosphate monohydrate 156.7 mg - estramustine

Flalgo 140 mg medic. plaster sachet بلجيكا - الإنجليزية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

flalgo 140 mg medic. plaster sachet

ibsa farmaceutici italia s.r.l. - diclofenac epolamine 180 mg - eq. diclofenac sodium 140 mg - medicated plaster - 140 mg - diclofenac epolamine 180 mg - diclofenac